CERS Quote, Financials, Valuation and Earnings

Accuray, Inc. has a net margin of -3.78% compared to Cerus Corp.'s net margin of -13.47%. Cerus Corp.'s return on equity of -26.37% beat Accuray, Inc.'s return on equity of -60.6%.

Cerus Corp. has a consensus price target of $4.67, signalling upside risk potential of 119.09%. On the other hand Accuray, Inc. has an analysts' consensus of $2.53 which suggests that it could grow by 379.76%. Given that Accuray, Inc. has higher upside potential than Cerus Corp., analysts believe Accuray, Inc. is more attractive than Cerus Corp..

Cerus Corp. has a beta of 1.511, which suggesting that the stock is 51.144% more volatile than S&P 500. In comparison Accuray, Inc. has a beta of 1.192, suggesting its more volatile than the S&P 500 by 19.162%.

Cerus Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Accuray, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cerus Corp. pays -- of its earnings as a dividend. Accuray, Inc. pays out -- of its earnings as a dividend.

Cerus Corp. quarterly revenues are $57.8M, which are smaller than Accuray, Inc. quarterly revenues of $102.2M. Cerus Corp.'s net income of -$2.2M is higher than Accuray, Inc.'s net income of -$13.8M. Notably, Cerus Corp.'s price-to-earnings ratio is -- while Accuray, Inc.'s PE ratio is 149.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cerus Corp. is 1.97x versus 0.14x for Accuray, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Alphatec Holdings, Inc. has a net margin of -3.78% compared to Cerus Corp.'s net margin of -10.21%. Cerus Corp.'s return on equity of -26.37% beat Alphatec Holdings, Inc.'s return on equity of -1092.5%.

Cerus Corp. has a consensus price target of $4.67, signalling upside risk potential of 119.09%. On the other hand Alphatec Holdings, Inc. has an analysts' consensus of $24.62 which suggests that it could grow by 89.06%. Given that Cerus Corp. has higher upside potential than Alphatec Holdings, Inc., analysts believe Cerus Corp. is more attractive than Alphatec Holdings, Inc..

Cerus Corp. has a beta of 1.511, which suggesting that the stock is 51.144% more volatile than S&P 500. In comparison Alphatec Holdings, Inc. has a beta of 1.020, suggesting its more volatile than the S&P 500 by 1.994%.

Cerus Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alphatec Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cerus Corp. pays -- of its earnings as a dividend. Alphatec Holdings, Inc. pays out -- of its earnings as a dividend.

Cerus Corp. quarterly revenues are $57.8M, which are smaller than Alphatec Holdings, Inc. quarterly revenues of $212.9M. Cerus Corp.'s net income of -$2.2M is higher than Alphatec Holdings, Inc.'s net income of -$21.7M. Notably, Cerus Corp.'s price-to-earnings ratio is -- while Alphatec Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cerus Corp. is 1.97x versus 2.56x for Alphatec Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nephros, Inc. has a net margin of -3.78% compared to Cerus Corp.'s net margin of 7.07%. Cerus Corp.'s return on equity of -26.37% beat Nephros, Inc.'s return on equity of 16.22%.

Cerus Corp. has a consensus price target of $4.67, signalling upside risk potential of 119.09%. On the other hand Nephros, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 67.96%. Given that Cerus Corp. has higher upside potential than Nephros, Inc., analysts believe Cerus Corp. is more attractive than Nephros, Inc..

Cerus Corp. has a beta of 1.511, which suggesting that the stock is 51.144% more volatile than S&P 500. In comparison Nephros, Inc. has a beta of 1.420, suggesting its more volatile than the S&P 500 by 41.997%.

Cerus Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nephros, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cerus Corp. pays -- of its earnings as a dividend. Nephros, Inc. pays out -- of its earnings as a dividend.

Cerus Corp. quarterly revenues are $57.8M, which are larger than Nephros, Inc. quarterly revenues of $4.8M. Cerus Corp.'s net income of -$2.2M is lower than Nephros, Inc.'s net income of $337K. Notably, Cerus Corp.'s price-to-earnings ratio is -- while Nephros, Inc.'s PE ratio is 28.02x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cerus Corp. is 1.97x versus 2.32x for Nephros, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -3.78% compared to Cerus Corp.'s net margin of -316.61%. Cerus Corp.'s return on equity of -26.37% beat Plus Therapeutics, Inc.'s return on equity of --.

Cerus Corp. has a consensus price target of $4.67, signalling upside risk potential of 119.09%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1775.85%. Given that Plus Therapeutics, Inc. has higher upside potential than Cerus Corp., analysts believe Plus Therapeutics, Inc. is more attractive than Cerus Corp..

Cerus Corp. has a beta of 1.511, which suggesting that the stock is 51.144% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.788, suggesting its less volatile than the S&P 500 by 21.173%.

Cerus Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cerus Corp. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Cerus Corp. quarterly revenues are $57.8M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Cerus Corp.'s net income of -$2.2M is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Cerus Corp.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cerus Corp. is 1.97x versus 4.70x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.